Electra Raises $350M in Upsized IPO

Electra Therapeutics has completed one of the larger biotech listings of the year, providing another sign that public markets are reopening for selected life-sciences companies.

What happened

The company priced an upsized IPO of 23.3 million shares at $15 each, raising approximately $350 million.

Electra began trading on Nasdaq under the ticker ETRA.

The late-stage biotech is developing precision medicines targeting signal-regulatory proteins involved in immune diseases and cancer. At pricing, its fully diluted market value was around $1 billion.

Why it matters

Biotech companies rely heavily on public markets because clinical development can consume hundreds of millions of dollars before a product reaches commercialisation.

A sizeable IPO therefore matters beyond one company. It provides new capital for drug development and can improve confidence among other private biotechs considering listings.

The bigger picture

The venture market has been dominated by AI, but biotech still depends on deep pools of specialised capital. Electra's offering suggests investors remain willing to fund late-stage clinical risk when the underlying programmes are sufficiently differentiated. That makes it a useful indicator of public-market appetite outside technology's AI cycle.